Cover Image

Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes: clinical research : vascular biology and medicine

The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and its shedding product [soluble LOX-1 (sLOX-1)] are implicated in atherosclerotic cardiovascular disease (ASCVD) pathogenesis. Herein, we examined the relationship of sLOX-1 with both fatal events and plaque progression in patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Kraler, Simon (Author) , Wenzl, Florian A (Author) , Georgiopoulos, Georgios (Author) , Obeid, Slayman (Author) , Liberale, Luca (Author) , von Eckardstein, Arnold (Author) , Muller, Olivier (Author) , Mach, François (Author) , Räber, Lorenz (Author) , Losdat, Sylvain (Author) , Schmiady, Martin O (Author) , Stellos, Konstantinos (Author) , Stamatelopoulos, Kimon (Author) , Camici, Giovanni G (Author) , Srdic, Annie (Author) , Paneni, Francesco (Author) , Akhmedov, Alexander (Author) , Lüscher, Thomas F. (Author)
Format: Article (Journal)
Language:English
Published: 14 May 2022
In: European heart journal
Year: 2022, Volume: 43, Issue: 19, Pages: 1849-1860
ISSN:1522-9645
DOI:10.1093/eurheartj/ehac143
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1093/eurheartj/ehac143
Verlag, kostenfrei, Volltext: https://academic.oup.com/eurheartj/article/43/19/1849/6553339?login=true
Get full text
Author Notes:Simon Kraler, Florian A Wenzl, Georgios Georgiopoulos, Slayman Obeid, Luca Liberale, Arnold von Eckardstein, Olivier Muller, François Mach, Lorenz Räber, Sylvain Losdat, Martin O. Schmiady, Konstantinos Stellos, Kimon Stamatelopoulos, Giovanni G. Camici, Annie Srdic, Francesco Paneni, Alexander Akhmedov, and Thomas F. Lüscher
Description
Summary:The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and its shedding product [soluble LOX-1 (sLOX-1)] are implicated in atherosclerotic cardiovascular disease (ASCVD) pathogenesis. Herein, we examined the relationship of sLOX-1 with both fatal events and plaque progression in patients with acute coronary syndromes (ACS).Plasma sLOX-1 was assessed at baseline in ACS and chronic coronary syndrome (CCS) patients prospectively recruited in the multicentre SPUM-ACS study, with sex- and age-matched healthy subjects serving as additional controls (n = 2924). Compared with both CCS and controls, ACS patients showed markedly elevated sLOX-1 levels (median, 2.00 and 2.00 vs. 35.08 pg/mL; P < 0.0001) which were independently associated with increased mortality risk over 30-day [tertile (T)3: adjusted hazard ratio (HR), 3.11; 95% confidence interval (CI), 1.44-10.61; P = 0.0055] and 1-year intervals (T3: adjusted HR, 2.04; 95% CI, 1.19-3.92; P = 0.0098). Results remained consistent after adjustment for GRACE 2.0 (T3: adjusted HR, 1.86; 95% CI, 1.04-3.74; P = 0.0391) and were primarily driven by the pronounced relationship of sLOX-1 with cardiovascular mortality at 30 days (T3: adjusted HR, 3.81; 95% CI, 1.62-19.62; P = 0.0036) and at 1 year (T3: adjusted HR, 2.29; 95% CI, 1.19-5.34; P = 0.0148). In ACS patients undergoing serial intracoronary imaging and statin therapy, sLOX-1 dropped significantly in those with coronary plaque regression at 1 year (ΔsLOX-1: −4.64 ± 1.80; P = 0.0057), and showed a good discrimination for predicting plaque progression (area under the curve = 0.74; 95% CI, 0.59-0.86; P = 0.0031).Plasma sLOX-1 levels are increased during ACS and predict fatal events beyond traditional and emerging risk factors. Persistently high sLOX-1 associates with coronary plaque progression in patients with established ASCVD.NCT01000701.
Item Description:Artikel vorab online veröffentlicht: 24. März 2022
Gesehen am 17.09.2024
Physical Description:Online Resource
ISSN:1522-9645
DOI:10.1093/eurheartj/ehac143

Similar Items